The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


Drug Intelligence & Clinical Pharmacy: Vol. 21, No. 7, pp. 590-593.
© 1987 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thompson, D.
Right arrow Articles by Trammel, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thompson, D.
Right arrow Articles by Trammel, H.


Research Articles

Therapeutic dosing of pralidoxime chloride

DF Thompson, GD Thompson, RB Greenwood, and HL Trammel

Pralidoxime chloride is a useful agent in the treatment of organophosphate poisoning. Poisindex, a widely used poisoning treatment resource, recommends dosing pralidoxime chloride as an intermittent iv infusion every 8-12 hours, whereas other authors have used continuous iv infusion with good results. Available animal data suggest that a serum concentration of 4 micrograms/ml may be a minimal level to protect against the toxic effects of organophosphates. Pharmacokinetic simulations, based on parameters obtained from healthy nonpoisoned subjects, show that pralidoxime levels fall rapidly to less than 4 micrograms/ml within 1.5-2 hours after a 1-g iv bolus. Continuous iv infusion (0.5 g/h) maintains pralidoxime levels greater than 4 micrograms/ml throughout the length of infusion. We conclude that continuous iv infusion of pralidoxime chloride may be the preferred method of administration in patients with acute organophosphate poisoning. Clinical trials will be necessary to document the effectiveness of this regimen.


This article has been cited by other articles:


Home page
J Intensive Care MedHome page
S. W. Wiener and R. S. Hoffman
Nerve Agents: A Comprehensive Review
J Intensive Care Med, January 1, 2004; 19(1): 22 - 37.
[Abstract] [PDF]


Home page
QJMHome page
M. Eddleston, L. Szinicz, P. Eyer, and N. Buckley
Oximes in acute organophosphorus pesticide poisoning: a systematic review of clinical trials
QJM, May 1, 2002; 95(5): 275 - 283.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1987 by Harvey Whitney Books Company.